AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$TARS

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 3:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tarsus Pharmaceuticals Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TARSBearishMed
01

Why it matters

The raised sales guidance and detailed expense outlook provide fresh material for traders.

02

Market read

New guidance could move TARS stock and influence related biotech names.

03

What to watch

Potential delays in Europe/Japan filings and high cash burn could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Tarsus Pharmaceuticals (NASDAQ:TARS) reported Q3 results and updated its 2026 outlook.

Company-level read

Ticker impact

$TARSBearishHigh confidence
Context

Tarsus raised its 2026 sales outlook to $715M-$730M and provided detailed Q3 expense guidance.

Expected impact

likely upward pressure as investors price in higher sales outlook

Evidence & confidence

The company increased its sales forecast and detailed spending plans, which are material new data for a biotech stock.

Market effects

Sector

Higher outlook may lift other ophthalmic biotech peers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to investors tracking US-listed biotech stocks.

Counterpoint

What could challenge this read

Guidance may be overly optimistic given pending regulatory filings.

Key entities

  • company
    Tarsus Pharmaceuticals

    Commercial-stage ophthalmic pharma company.

Read at source← All news

StoryTarsus posts acquisition-driven Q3 loss and raises XDEMVY outlook

Also covered by

2 outlets

Related articles

NOV 3
$TARSMed

Tarsus Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales si

SEC EDGAR 8-K2 min
SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min